<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094769</url>
  </required_header>
  <id_info>
    <org_study_id>2010/10</org_study_id>
    <secondary_id>58667</secondary_id>
    <nct_id>NCT01094769</nct_id>
  </id_info>
  <brief_title>Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease</brief_title>
  <official_title>Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker IDI Heart and Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether moxonidine is effective in reducing urine
      albumin levels in patients with diabetic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the effect of moxonidine in lowering urine albumin excretion and
      limiting further damage to the kidneys in patients with diabetic nephropathy. Reducing urine
      albumin excretion in type 2 diabetic patients is an indicator of successful treatment.
      Previous studies have shown that drugs that work in a similar fashion to moxonidine
      (intervene with the sympathetic nervous system)have been very effective in reducing the
      amount of albumin in the urine and are associated with long term renal and cardiovascular
      protection.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine albumin/creatinine ratio (UACR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary outcome measure is the difference in the change of UACR between active treatment and placebo from baseline to week 12 of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>muscle sympathetic nerve activity (MSNA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Secondary outcome measure is the difference between active and placebo treatment in the change from baseline to week 12 of treatment in muscle sympathetic nerve activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine</intervention_name>
    <description>Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.</description>
    <arm_group_label>Moxonidine</arm_group_label>
    <other_name>Physiotens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>lactose capsule taken once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 18-75 years

          -  diabetic nephropathy as defined by the mean of three consecutive early morning urinary
             albumin-creatinine ratios (UACR) of &gt;300mg per gram, or &gt; 200mg per gram in patients
             receiving therapy targeted at blockade of the RAS

        Exclusion Criteria:

          -  non-diabetic kidney disease

          -  UACR of more than 3500mg per gram, an estimated glomerular filtration rate of less
             than 30ml/min/1.73m2.

          -  chronic urinary tract infection.

          -  severe hypertension

          -  heart failure NYHA class II-IV

          -  major cardiovascular disease within the previous 6 months

          -  left ventricular ejection fraction &lt;55%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus P Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart and Diabetes Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gavin W Lambert, BSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart and Diabetes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus P Schlaich, MD</last_name>
    <phone>61 3 8532 1502</phone>
    <email>markus.schlaich@bakeridi.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gavin W Lambert, BSc PhD</last_name>
    <phone>61 3 8532 1346</phone>
    <email>gavin.lambert@bakeridi.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alfred &amp; Baker Medical Unit</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Markus P Schlaich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gavin W Lambert, BSc PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

